Insider Selling: Jounce Therapeutics, Inc. (NASDAQ:JNCE) CFO Sells $18,231.72 in Stock


Share on StockTwits

Jounce Therapeutics, Inc. (NASDAQ:JNCE) CFO Kimberlee C. Drapkin sold 2,697 shares of the business’s stock in a transaction dated Thursday, January 7th. The stock was sold at an average price of $6.76, for a total value of $18,231.72. Following the sale, the chief financial officer now directly owns 59,011 shares of the company’s stock, valued at $398,914.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of JNCE stock opened at $7.33 on Thursday. The stock has a market cap of $292.11 million, a PE ratio of -2.44 and a beta of 1.36. The stock has a 50-day moving average of $6.88 and a 200-day moving average of $6.99. Jounce Therapeutics, Inc. has a one year low of $2.85 and a one year high of $11.72.

Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.36). Analysts anticipate that Jounce Therapeutics, Inc. will post -2.21 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System grew its position in shares of Jounce Therapeutics by 6.3% in the 3rd quarter. California State Teachers Retirement System now owns 26,139 shares of the company’s stock valued at $213,000 after purchasing an additional 1,548 shares during the period. Colony Group LLC acquired a new position in shares of Jounce Therapeutics in the 3rd quarter valued at approximately $82,000. Cubist Systematic Strategies LLC acquired a new position in shares of Jounce Therapeutics in the 3rd quarter valued at approximately $442,000. Squarepoint Ops LLC acquired a new position in shares of Jounce Therapeutics in the 3rd quarter valued at approximately $261,000. Finally, Morgan Stanley grew its position in shares of Jounce Therapeutics by 39.8% in the 3rd quarter. Morgan Stanley now owns 33,999 shares of the company’s stock valued at $278,000 after purchasing an additional 9,671 shares during the period. Institutional investors and hedge funds own 63.62% of the company’s stock.

Several analysts have weighed in on the company. BidaskClub raised Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 1st. Raymond James cut Jounce Therapeutics from a “strong-buy” rating to a “market perform” rating in a report on Monday, November 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Jounce Therapeutics in a research note on Friday, December 4th. Roth Capital lowered their price target on Jounce Therapeutics from $28.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, November 10th. Finally, ValuEngine raised Jounce Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. Jounce Therapeutics presently has an average rating of “Hold” and a consensus price target of $11.38.

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer.

Further Reading: Why is the price target of stocks important?

Insider Buying and Selling by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.